Leveraging external data in the design and analysis of clinical trials in neuro-oncology

被引：0

作者：

Rahman, Rifaquat ^{[1
]}

Ventz, Steffen ^{[2
]}

McDunn, Jon ^{[4
]}

Louv, Bill ^{[4
]}

Reyes-Rivera, Irmarie ^{[5
]}

Polley, Mei-Yin C. ^{[6
]}

Merchant, Fahar ^{[7
]}

Abrey, Lauren E. ^{[8
]}

Allen, Joshua E. ^{[9
]}

Aguilar, Laura K. ^{[10
]}

Aguilar-Cordova, Estuardo ^{[10
]}

Arons, David ^{[11
]}

Tanner, Kirk ^{[11
]}

Bagley, Stephen ^{[12
]}

Khasraw, Mustafa ^{[13
]}

Cloughesy, Timothy ^{[14
]}

Wen, Patrick Y. ^{[3
]}

Alexander, Brian M. ^{[1
,15
]}

Trippa, Lorenzo ^{[2
]}

Roche, F. Hoffmann-La

Aguilar-Cordova, E.

Tanner, K.

机构：

[1] Harvard Med Sch, Dept Radiat Oncol, Dana Farber Brigham & Womens Canc Ctr, Boston, MA 02115 USA

[2] Harvard TH Chan Sch Publ Hlth, Dept Data Sci, Boston, MA USA

[3] Harvard TH Chan Sch Publ Hlth, Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA USA

[4] Project Data Sphere, Morrisville, NC USA

[5] F Hoffmann La Roche, Basel, Switzerland

[6] Univ Chicago, Dept Publ Hlth Sci, Chicago, IL 60637 USA

[7] MedicennaTherapeut, Toronto, ON, Canada

[8] Novartis, Basel, Switzerland

[9] Chimerix, Durham, NC USA

[10] Candel Therapeut, Needham, MA USA

[11] Natl BrainTumor Soc, Newton, MA USA

[12] Univ Penn, Perelman Sch Med, Div Hematol & Oncol, Philadelphia, PA 19104 USA

[13] Duke Univ, Med Ctr, Preston Robert Tisch Brain Tumor Ctr, Dept Neurosurg, Durham, NC USA

[14] Univ Calif Los Angeles, Dept Neurol, David Geffen Sch Med, Los Angeles, CA USA

[15] Fdn Med, Cambridge, MA USA

来源：

LANCET ONCOLOGY | 2021年 / 22卷 / 10期

基金：

美国国家卫生研究院;

关键词：

HISTORICAL CONTROL DATA; REAL-WORLD EVIDENCE; SINGLE-ARM; ADJUVANT PACLITAXEL; ADJUSTMENT; SURVIVAL; RANDOMIZATION; TEMOZOLOMIDE; TRASTUZUMAB; BEVACIZUMAB;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Integration of external control data, with patient-level information, in clinical trials has the potential to accelerate the development of new treatments in neuro-oncology by contextualising single-arm studies and improving decision making (eg, early stopping decisions). Based on a series of presentations at the 2020 Clinical Trials Think Tank hosted by the Society of Neuro-Oncology, we provide an overview on the use of external control data representative of the standard of care in the design and analysis of clinical trials. High-quality patient-level records, rigorous methods, and validation analyses are necessary to effectively leverage external data. We review study designs, statistical methods, risks, and potential distortions in using external data from completed trials and real-world data, as well as data sources, data sharing models, ongoing work, and applications in glioblastoma.

引用

页码：E456 / E465

页数：10

共 50 条

[21] The Comprehensive Neuro-Oncology Data Repository (CONDR): A Research Infrastructure to Develop and Validate Imaging Biomarkers
Fouke, Sarah Jost
Benzinger, Tammie L.
Milchenko, Mikhail
LaMontagne, Pamela
Shimony, Joshua S.
Chicoine, Michael R.
Rich, Keith M.
Kim, Albert H.
Leuthardt, Eric C.
Keogh, Bart
Marcus, Daniel S.
NEUROSURGERY, 2014, 74 (01) : 88 - 98
[22] A New Era of Neuro-Oncology Research Pioneered by Multi-Omics Analysis and Machine Learning
Takahashi, Satoshi
Takahashi, Masamichi
Tanaka, Shota
Takayanagi, Shunsaku
Takami, Hirokazu
Yamazawa, Erika
Nambu, Shohei
Miyake, Mototaka
Satomi, Kaishi
Ichimura, Koichi
Narita, Yoshitaka
Hamamoto, Ryuji
BIOMOLECULES, 2021, 11 (04)
[23] Biased by design? Clinical trials and patient benefit in oncology
Pantziarka, Pan
Verbaanderd, Ciska
Meheus, Lydie
FUTURE ONCOLOGY, 2020, 16 (03) : 4419 - 4423
[24] Neuro-Oncology Clinical Debate: PCV or temozolomide in combination with radiation for newly diagnosed high-grade oligodendroglioma
Ruff, Michael W.
Buckner, Jan C.
Johnson, Derek R.
van den Bent, Martin J.
Geurts, Marjolein
NEURO-ONCOLOGY PRACTICE, 2019, 6 (01) : 17 - 21
[25] A conservative approach to leveraging external evidence for effective clinical trial design
Rigat, Fabio
PHARMACEUTICAL STATISTICS, 2024, 23 (01) : 81 - 90
[26] The use of external control data for predictions and futility interim analyses in clinical trials
Ventz, Steffen
Comment, Leah
Louv, Bill
Rahman, Rifaquat
Wen, Patrick Y.
Alexander, Brian M.
Trippa, Lorenzo
NEURO-ONCOLOGY, 2022, 24 (02) : 247 - 256
[27] RMST for Interval-Censored Data in Oncology Clinical Trials
Gao, Xiyuan
Lyu, Tianmeng
Xu, Menghao
Hampson, Lisa V.
Du, Yan
Lin, Renxin
Yateman, Nigel
Tian, Lu
Sun, Jianguo
STATISTICS IN MEDICINE, 2025, 44 (05)
[28] Deep neural networks for neuro-oncology: Towards patient individualized design of chemo-radiation therapy for Glioblastoma patients
Zade, Amir Ebrahimi
Haghighi, Seyedhamidreza Shahabi
Soltani, M.
JOURNAL OF BIOMEDICAL INFORMATICS, 2022, 127
[29] Implementation of neuro-oncology service reconfiguration in accordance with NICE guidance provides enhanced clinical care for patients with glioblastoma multiforme
Guilfoyle, M. R.
Weerakkody, R. A.
Oswal, A.
Oberg, I.
Jeffery, C.
Haynes, K.
Kullar, P. J.
Greenberg, D.
Jefferies, S. J.
Harris, F.
Price, S. J.
Thomson, S.
Watts, C.
BRITISH JOURNAL OF CANCER, 2011, 104 (12) : 1810 - 1815
[30] Patient-Specific Mathematical Neuro-Oncology: Using a Simple Proliferation and Invasion Tumor Model to Inform Clinical Practice
Jackson, Pamela R.
Juliano, Joseph
Hawkins-Daarud, Andrea
Rockne, Russell C.
Swanson, Kristin R.
BULLETIN OF MATHEMATICAL BIOLOGY, 2015, 77 (05) : 846 - 856

← 1 2 3 4 5 →